Substituted heterocyclic acyl-tripeptides useful as thrombin...

Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Tripeptides – e.g. – tripeptide thyroliberin – etc.

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S018700, C514S019300

Reexamination Certificate

active

10606422

ABSTRACT:
The invention is directed to substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators, their use in wound healing and preventing platelet aggregation. Pharmaceutical compositions comprising the substituted heterocyclic acyl-tripeptides of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.

REFERENCES:
patent: 4314936 (1982-02-01), Yaron et al.
patent: 5391705 (1995-02-01), Neises et al.
patent: 5696231 (1997-12-01), Abelman et al.
patent: 6017890 (2000-01-01), Oekstra et al.
patent: 6069232 (2000-05-01), Malikayl et al.
patent: 0503203 (1992-09-01), None
patent: 9201875 (1992-06-01), None
patent: 9901290 (1999-11-01), None
patent: WO92/04371 (1992-03-01), None
patent: WO99/42475 (1999-08-01), None
Cindy L. A. Jones, “Responese of a human megakaryocytic cell line to thrombin: Increase in Intracellular free calcium and mitogen release”, Biochimica et Biophysica Acta, 1136 (1992) 272-282.
Hoekstra, W.J. et al., “Thrombin Receptor (PAR-1) Antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motif”, Biorganic & Medical Chemistry Letters, GB, Oxford, vol. 8, No. 13, Jul. 7, 1998, pp. 1649-1654.
Bernatowicz E.A., “Development of potent thrombin receptor antagonist peptides”, Journal of Medicinal Chemistry, vol. 39, 1996, pp. 4879-4887.
McComsey, D.F. et al., “Heterocycle-peptide hybrid compounds. Aminotriazole-containing agonists of the thrombin receptor (PAR-1)”, Bioorganic & Medicinal Chemistry Letters, GB, Oxford, vol. 9, No. 10, May 17, 1999, pp. 1423-1428.
Yasuo Sugama et al., “Thrombin-Induced Expression of Endothelial P-Selection and Intercellular Adhesion Molecule-1: A Mechanism for Stabilizing Neutrophil Adhesion”, The Journal of Cell Biology, vol. 119, No. 4, Nov. 1992, pp. 935-944.
Thien-Khal & H. Vu et al., “Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation”, Cell, vol. 64, Mar. 1991, pp. 1057-1068.
Dimitris N. Tatakis et al., “Thrombin Effects on Osteoblastic Cells—II. Structure-Function Relastionships”, Biochemical and Biophysical Research Communications, vol. 174, No. 1, Jan. 1991, pp. 181-188.
Linde et al, “Pharmacological treatment for prevention of restenosis” Expert Opinion, 2001, pp. 281-302, Ashley Publications, www.ashley-pub.com, Canada.
Ischinger, Thomas, “Antithrombotics in Interventional Cardiology: Optimizing Treatment and Strategies”, 1998, pp. 25L-28L, vol. 28 (5B), Excerpta Medica, Inc., The American Journal of Cardiology.
Schwartz, Robert, “Pathophysiology of Restenosis: Interaction of Thrombosis, Hyperplasia, and/or Remodeling”, Excerpta Medica, Inc., A Symposium: International Vascular Medicine, 1998, pp. 14E-17E.
Marx et al, “Rampamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells” Circulation Research, 1995 American Heart Association, Inc. 1995, vol. 76, pp. 412-417.
Sollott et al, “Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation After Angioplasty in the Rat” The Journal of Clinical Investigation, Inc., Apr. 1995, pp.1869-1876, The Journal of Clinical Investigation, Inc., vol. 95, pp. 1869-1876.
Suzuki et al, “Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model” 2001 American Heart Association, pp. 1188-1193, USA.
Andrade-Gordon et al, “Adminstration of a Potent Antagonist of Protease-Activated Receptor-1 (PAR-1) Attenuates Vascular Restenosis Following Balloon Angioplasty in Rats” , The Journal of Pharmacology and Experimental Therapeutics, 2001, 298: No. 1, pp. 34-42, USA.
Chesebro et al, “Antithrombotic Therapy and Progression of Coronary Artery Disease, Antiplatelet vs. Antithrombins”, Circulation, 1992, 86[suppl III]: III-100-III-111.
White, Harvey, “Newer Antiplatelet Agents in Acute Coronary Syndromes” Cardiology Dept. Green Lane Hospital, New Zealand, e-mail; harveyw@ahsl.co.nz, 1999, Mosby, Inc.
Verstraete et al, “Novel Antithrombotic Drugs in Development”, Center for Molecular and Vascular Biology, University of Leuven, Belgium, Drugs, 1995, pp. 856-884, Adis International Limited.
Weksler, Babette, “Antiplatelet Agents in Stroke Prevention” Dept. of Medicine, New York Presbyterian Hospital—Weill Cornell Medical Center, New York, NY USA, 2000; 10(suppl 5) 41-48, www.karger.com/journals/ced.
Mousa, Shaker, “Antiplatelet therapies: from aspirin to GPllb/llla-receptor antagonists and beyond”, Therapeutic Focus, Elsevier Science Ltd., 1999, pp. 552-530, vol. 4, No. 12, USA.
Derian et al, “Blockage of the Thrombin Receptor Protease-Activated Receptor-1 with a Small Molecule Antagonist Prevents Thrombus and Vascular Occlusion in Non-Human Primates”, The Journal of Pharmacology and Experimental Therapeutics, 2003, pp. 855-861, vol. 304, No. 2, The American Society for Pharmacology and Experimental Therapeutics, USA.
Bevilacqua et al, “Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neurtrophils Related to Complement Regulatory Porteins and Lectins,” Science, 1989, pp.1160-1165, vol. 243.
Jalink et al, “Thrombin Receptor Activation Causes Rapid Neural Cell Rounding and Neurite Retraction Independent of Classic Sound Messengers,” The Journal of Cell Biology, 1992, pp. 411-419, vol. 118, No. 2, The Rockefeller University Press.
Hung et al, “Thrombin-induced Events in Non-Platelet Cells are Mediated by the unique Proteolytic Mechanism Established for the Cloned Platelet Thrombin Receptor,” The Journal of Cell Biology, 1992, pp. 827-832, vol. 116, No. 3, The Rockefeller University Press.
Harlan et al, “α-Thrombin Induces Release of Platelet-derived Growth Factor-like Molecule(s) by Cultured Human Endothelial Cells,” the Journal of Cell Biology, 1986, pp. 1129-1133, vol. 103, The Rockefeller University Press.
Hwang et al, “Enzyme-Catalyzed Peptide Segment Condensation Using 5 (4 H) - Oxazolones as Acyl Donors,” The American Chemical Socieity, 1993, pp. 7912-7913, vol. 115.
Ahn et al, “Structure-Activity Relationships of Pyrroloquinazolines as Thrombin Receptor Antagonists,” Bioorganic and Medicinal Chemistry Letters, 1999, pp. 2073-2078, Letters 9, Elsevier Science, Ltd.
Carney et al, “Enhancement of Incisional Wound Healing and Neovascularization in Normal Rats by Thrombin and Synthetic Thrombin Receptor-activating Peptides,” Journal of Clin Invest, 1992, pp. 1469-1477, vol. 89, The American Society or Clinical Investigation, Inc.
Malik, Asrar B., Ph.D., “Thrombin-Induced Endothelial Injury,” Seminars In Thrombosis and Hemostasis, 1986, pp. 184-196, vol. 12, No. 3, Theieme Medical Publishers, New York, NY.
Derian et al, “Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates,” The Journal of Pharmacology and Experimental Therapeutics, 2003, pp. 855-861, vol. 304, No. 2, The American Society for Pharmacology and Experimental Therapeutics, USA.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Substituted heterocyclic acyl-tripeptides useful as thrombin... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted heterocyclic acyl-tripeptides useful as thrombin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocyclic acyl-tripeptides useful as thrombin... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3895330

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.